Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 3/20 | 0.42 |
| ▸ | NOS2 | P35228 | 3/20 | 0.42 |
| ▸ | F12 | P00748 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | PRKCI | P41743 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 4/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | AHR | P35869 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.37 |
| ▸ | CHUK | O15111 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | JAK3 | P52333 | 2/20 | 0.37 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5088055 | 0.98 | TRPA1 (0.44) | TRPA1NOS3NOS2F12PLAU | |
| SCHEMBL4550230 | 0.74 | PDE3B (0.58) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL27833574 | 0.74 | TRPA1 (0.45) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL961508 | 0.74 | PRKCI (0.48) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL1154939 | 0.74 | TRPA1 (0.45) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL1853729 | 0.74 | TRPA1 (0.45) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL1019530 | 0.74 | PDE3B (0.53) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL28315998 | 0.74 | TRPA1 (0.45) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL15058190 | 0.74 | TRPA1 (0.41) | TRPA1PRKCIAXLPIK3CDDRD1 | |
| SCHEMBL146920 | 0.70 | TRPA1 (0.39) | TRPA1PRKCIAXLPIK3CDDRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| WO-2025026997-A1 | SUBSTITUED BICYCLIC HETEROCYCLIC YAP-TEAD AND/OR TAZ-TEAD INHIBITORS | MERCK PATENT GMBH (DE) | 2025-02-06 | — | — | WO | disclosed |
| CN-118652251-A | 5-Azaindole compound, pharmaceutical composition and application thereof | 贵州大学 | 2024-09-17 | — | — | CN | disclosed |
| WO-2023146991-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| CN-113993870-B | Imidazo pyrimidine compound containing fused ring group, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| EP-3947388-A1 | COMPOUNDS TARGETING PRMT5 | Aligos Therapeutics, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113993870-A | Imidazo pyrimidine compound containing polycyclic group, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-01-28 | — | — | CN | disclosed |
| WO-2020205867-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020205867-A1 | COMPOUNDS TARGETING PRMT5 | ALIGOS THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534797-B2 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-05-07 | — | — | US | disclosed |
| WO-2008116816-A1 | COMBINATION OF CB2 LIGAND AND PARACETAMOL | GLAXO GROUP LIMITED (GB) | 2008-10-02 | — | — | WO | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | OSI PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007064993-A2 | BICYCLIC PROTEIN KINASE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | ACERTA PHARMA B.V. (NL) | 2006-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118499-A1 | 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors | IGF1R, MAP2K7, BRCA1 | TRPA1 2776/4885NOS3 1824/4885NOS2 2324/4885 |
| US-20070149521-A1 | Bicyclic protein kinase inhibitors | CDK1, MAP4K2, MAP4K3 | TRPA1 2017/4885NOS3 1222/4885NOS2 2123/4885 |
| US-20060235031-A1 | 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors | IGF1R, MAP2K7, BRCA1 | TRPA1 2776/4885NOS3 1824/4885NOS2 2324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.